125 results about "Cell invasion" patented technology

The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.

The invention provides a method and a composition used for evaluating patients with breast cancer, particularly the prognosis of the patients with the breast cancer at an early stage. The method of the invention comprises the detection of at least one of body samples, particularly the expression of at least two biological markers, wherein, the over-expression of the biological markers or the combination of the biological markers indicates the prognosis of the breast cancer. The body samples in a plurality of implementation proposals are the mammary tissue samples, particularly the primary breast tumor samples. The biological markers of the invention are proteins and/or genes, and the over-expression indicates the good or poor cancer prognosis. The concerned biological markers include the proteins and genes which participate in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, cell invasion, protein hydrolysis or transfer. The biological marker-specific antibody is used on the protein level or the nucleic acid hybridization technology is used on the nucleic acid level for detecting the over-expression of the concerned biological markers in certain aspects of the invention.

The present invention provides cyclic RNA circ-ZKSCAN1 use, the objective existence of circ-ZKSCAN1 gene is first confirmed; expression status of the circ-ZKSCAN1 gene in a patient with hepatocarcinoma is detected to find that the expression level of the circ-ZKSCAN1 gene is significantly reduced; hepatoma cells transfected with circ-ZKSCAN1 gene shRNA sequence are compared with control hepatoma cells transfected with an empty vector to find that the proliferation rate, cell migration ratio and cell invasion ability and the like are significantly improved. The circ-ZKSCAN1 gene and a circ-ZKSCAN1 gene expression product are used as a hepatoma diagnostic marker, so that hepatoma diagnosis is more accurate and rapid, and the circ-ZKSCAN1 gene as a target gene for preparing hepatoma treatment drugs provides a new therapeutic target and therapeutic approach.

A composition for preventing malaria infection including a protease inhibitor. A pharmaceutical composition for preventing malaria infection including a protease inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by inhibiting circumsporozoite protein processing or by inhibiting a protease of a sporozoite. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing.

The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

Apparatus and methods to improve the Boyden chamber used in cellular biological measurements, allowing quantitative optical microscopy of biological cells in situ without using fluorescent probes or optical staining. In the preferred embodiment, a thin porous membrane separating top and bottom reservoirs includes an array of precisely positioned micropores pores manufactured using a laser-based photo-machining (ablation) process. The membrane may be composed of polyethylene terephthalate (PET), polycarbonate, polyimide, polyether ether ketone (PEEK) or other appropriate material. The pores formed in the membrane may have diameters in the range of 1 to 15 microns and spaced apart at a distance ranging from 10 to 200 microns. A plurality of upper and lower reservoirs may be provided to form a multi-well plate. The invention finds application in a wide range of potential biological applications where Boyden chamber geometries are currently used including co-culture studies, tissue remodeling studies, cell polarity determinations, endocrine signaling, cell transport, cell permeability, cell invasion and chemotaxis assays.

The present invention provides novel assay systems and methods for monitoring cell invasion by protozoal parasites. The present invention further provides methods of using these assays systems to identify compounds that treat or prevent protozoal infection. The present invention further provides pharmaceutical compositions that have anit-protozoal activity and methods of treating infections.

The present invention relates to method for the preparation of glycosaminoglycan compositions, isolated glycosaminoglycan compositions obtainable therefrom, glycosaminoglycan compositions, kits and use thereof. More specifically, the present invention provides a method for isolating glycosaminoglycan compositions of the invention from human follicular fluid. The compositions, related methods and uses according to the present invention are useful in the treatment and/or prevention of thrombotic diseases, cell proliferation disorders, proteolysis and inflammation mediated cell invasion and infertility.

The present invention relates to a human cervical carcinoma metastasis relevant new long chain non-coding RNA sequence, a target sequence for RNA interference, a short hairpin sequence for encoding interference target, a RNAi target sequence containing the long chain non-coding RNA sequence, a shRNA short hairpin nucleic acid sequence recombinant vector and a ecombinant. The present invention further relates to a separation method and uses of the new long chain non-coding RNA sequence. According to the present invention, the long chain non-coding RNA sequence is obtained from the cervical carcinoma related cDNA library through RACE amplification through a bioinformatics method, and the function and the uses of the RNA sequence are verified through sequencing, hybridization, cell proliferation, cell invasion and other tests; the sequence-specific shRNA for RNAi, the siRNA sequence and the recombinant vector are designed, and the functions of the siRNA and the shRNA are verified; and the long chain non-coding RNA sequence, the RNAi interference target and the shRNA short hairpin sequence provide important significance in early diagnosis and treatment of cervical carcinoma.

The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

The invention relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines, belongs to the field of biopharmaceutical research, and particularly relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines. The inventor firstly finds that the PNO1 can be used as an esophagus cancer treatment target point. The PNO1 inhibitor can restrain the proliferation rate of esophagus cancer cells, can restrain the cloning and forming capacity of the esophagus cancer cells, can promote esophagus cancer apoptosis, can restrain esophagus cancer cell migration, can restrain esophagus cancer cell transfer, and can restrain esophagus cancer cell invasion and transfer, so as to treat esophagus cancer, and a new direction is opened up for treatment of esophagus cancer.

The invention relates to a terahertz metamaterial chip for cell invasion and migration unmarked detection. A cell culture chamber, a porous film and a metamaterial chip layer are integrated, and by alocally enhanced electric field of the terahertz metamaterial in vertical micron distribution, in-situ unmarked detection of quantity of cells penetrating the porous film is performed to assess movement behaviors such as cell invasion and migration. A whole device is simple in structure, convenient to assemble, small in size, easy to integrate and reusable.

The invention provides a reagent or a kit for early diagnosis of hepatocellular carcinoma and an application of the reagent or the kit. Specifically, the invention provides an application of at least one of UBE2J2, ATP6V0D1 and STXBP2. The UBE2J2, ATP6V0D1 and STXBP2 show high expression in highly metastatic hepatocellular carcinoma cells. Tests on a plurality of hepatocellular carcinoma and para-carcinoma specimens prove that expression of the UBE2J2, ATP6V0D1 and STXBP2 in most hepatocellular carcinoma specimens is higher than that in para-carcinoma specimens. Based upon cell invasion assay, it proves that the UBE2J2, ATP6V0D1 and STXBP2 can regulate and control invasion capacity of the hepatocellular carcinoma cells. Therefore, the UBE2J2, ATP6V0D1 and STXBP2, as new targets for hepatocellular carcinoma diagnosis and treatment, have a potential prospect of clinical application.

The invention provides a cell bidirectional invasion monitoring method based on a micro-fluidic chip. According to the cell bidirectional invasion monitoring method, the micro-fluidic chip is adopted for monitoring the cell bidirectional invasion, the inducing or inhibiting effects of different cells or factors on the invasion of a target cell can be simultaneously observed and compared, and the inducing or inhibiting effects of one certain cell or factor on the invasion of different target cells also can be simultaneously observed. The micro-fluidic chip is mainly composed of three main channels and two collagen channels, wherein the three main channels used for cell culture horizontally communicate with the two collagen channels used for the cell migration observation; the left of the middle main channel (1) is connected with the left collagen channel (2), the right of the middle main channel (1) is connected with the right collagen channel (4), the left of the left collagen channel (2) is connected with the left main channel (3), and the right of the right collagen channel (4) is connected with the right main channel (5). The method has the feature of tracking the cell movement in real time, the accurate locating for the cell movement is realized, and meanwhile, the cell invasion capacity and selectivity can be observed and compared.

The invention discloses a novel anthraquinone polypyridine ligand and a preparation method thereof. The anthraquinone polypyridine ligand is simple in synthetic method and can be further used for preparing binuclear ruthenium complexes. The prepared anthraquinone polypyridine binuclear ruthenium complexes as shown in a general formula of [(bpy) 2Ru (X-biipad) Ru (bpy) 2] (ClO4)4 have the advantages of stable structure and high water solubility, can effectively inhibit the migration of tumor cells and cell invasion according to the results of cell wound scratch assay and cell invasion assay, and can be used for preparing novel antineoplastic drugs for inhibiting tumor metastasis.

The present invention relates to a Gremlin-1 antibody that inhibits Gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR-2), thus providing the effect of treating cancer. The antibody of the present invention inhibits cell migration, cell invasion and cell proliferation which are dependent on Gremlin-1, and therefore, can be effectively used in treating cancer or immune disease.

The present invention discloses applications of targeted HOTAIR-inhibiting small RNA in preparation of anti-prostate cancer drugs. According to the present invention, the DNA sequence encoding HOTAIR gene is located between the gene HOXC11 and the gene HOXC12 of the chromosome 12, HOTAIR is a spliced polynucleotide transcription product having a length of 2158 nt, and the sequences encoding HOTAIR comprises five short exons and a long exon; the small RNA comprises a variety of siRNA sequences, wherein the small RNA can downregulate the expression of the HOTAIR gene in prostate cancer cells in a targeted manner so as to induce cell cycle arrest and inhibits cell invasion and migration ability, such that the small RNA can be used for the preparation of the anti-prostate cancer drugs; the siRNA of the present invention has characteristics of simple preparation, low cost, less consumption and exact inhibition effect, wherein the good inhibition effect can be achieved only with the 50 nM transfection concentration; and the siRNA inhibits the gene expression while the integrity of the genome can not be damaged.

The invention discloses a Zeylenone inhibiting gastric carcinoma cell proliferation, invasion, migration and apoptosis induction, and provides application of the Zeylenone or nano-micelle thereof in preparing at least one kind of products of 1) a product treating or preventing gastric carcinoma, 2) a product inhibiting gastric carcinoma cell proliferation or growth, 3) a product inducing gastric carcinoma cell apoptosis and 4) a product inducing gastric carcinoma cell invasion and/ or migration. The Zeylenone inhibiting gastric carcinoma cell proliferation, invasion, migration and apoptosis induction has the advantages that it is firstly found that Zey can inhibit gastric carcinoma cell invasion, migration and apoptosis induction, so zey is a very potential therapeutic drug, certainly caninhibit the growth of the gastric carcinoma and has a pharmaceutical effect of anti-tumor in vivo.

The invention discloses an application of MAGE-A9 in the preparation of lung cancer treatment drugs. The MAGE-A9 is a target for non-small cell lung cancer gene therapy, and the drugs are designed against the target. Influences of down-regulation of MAGE-A9 gene expression on NSCLC (non-small cell lung cancer) cell invasion, migration and other biological behaviors are researched in test of in vitro environment, and a result of the researches shows that a specific siRNA sequence can effectively inhibit expression of the MAGE-A9 protein in the NSCLC cell strains SPC-A-1 and NCI-H1975. After the MAGE-A9 expression is inhibited through RNA interference, propagation of the SPC-A-1 and NCI-H1975 cells is slow, apoptosis increases, and the cell migration and invasion ability is reduced. The MAGE-A9 is the target for non-small cell lung cancer gene therapy, and can be widely applied in the preparation of the lung cancer treatment drugs.

Disclosed are compositions and methods useful in the reduction of p11 protein activity in cancer cells. P11 protein is demonstrated to affect plasmin production and activity, MMP activity, plasminogen activation, antiangiogenic plasmin fragment production, cell invasion, tumor development and metastasis. Compositions that modulate levels of p11 either up or down are demonstrated to be effective in reducing tumor development. Also disclosed are cancer treatment methods that employ compositions that modulate p11 activity and clonal cell lines and assays useful for the identification of compositions that modulate p11 activity.

The present application relates to the compounds of formula I (I) as well as their use for inhibiting at least one of AKT-1, FAK and PKCα and in the treatment and/or prevention of metastatic diseases.